Hidekazu Ishida joined Eisai Co., Ltd. in 2020. Previously, he worked for an investment banking of SMBC Nikko securities and pursued deal originations in the Pharmaceutical/Healthcare sectors.

Furthermore, he was responsible for increasing the valuations of startups by supporting BD activities as IPO professional services, and achieved a lot, especially in the digital health field. He also took care of underwriting equity finance by venture companies as investment deals.

Before that, he engaged in planning and establishing new business with other sectors such as insurance companies in Otsuka pharmaceutical. His carrier started as a researcher to develop novel drugs for Tuberculosis and Malaria in the pharmaceutical in 2011. D.V.M, Ph.D (Immunology/Infectious Disease)